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Introduction: The evaluation of cognitive impairment in adulthood merits attention in societies in transition and
especially in people with chronic diseases. Screening tools available for clinical practice and epidemiological
studies have been designed in high-income but not in resource-constrained settings. The aim of this study was
to assess the agreement and bias of three common tools used for screening of cognitive impairment in people
with hypertension: the modiﬁed Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment
(MoCA), and the Leganés Cognitive Test (LCT).
Methods: A cross-sectional study enrolling participants with hypertension from a semi-urban area in Peru was
performed. The three screening tools for cognitive impairmentwere applied on three consecutive days. The prev-
alence of cognitive impairment was calculated for each test. Pearson's correlation coefﬁcients, Bland-Altman
plots, and Kappa statistics were used to assess agreement and bias between screening tools.
Results:We evaluated 139 participants, mean age 76.5 years (SD ± 6.9), 56.1% females. Cognitive impairment
was found in 28.1% of individuals using LCT, 63.3% using MMSE, and 100% using MoCA. Correlation coefﬁcients
ranged from 0.501 between LCT and MoCA, to 0.698 between MMSE and MoCA. Bland-Altman plots conﬁrmed
bias between screening tests. The agreement between MMSE and LCT was 60.4%, between MMSE and MoCA
was 63.3%, and between MoCA and LCT was 28.1%.
Conclusions: Three of the most commonly used screening tests to evaluate cognitive impairment showed major
discrepancies in a resource-constrained setting, signaling towards a sorely need to develop and validate appro-
priate tools.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Cognitive impairment is a growing public health concern [1–3].
Aging, lifestyles and chronic diseases, mainly hypertension and type 2
diabetes mellitus, are the most important contributing factors for the
development of and progression towards cognitive impairment [4]. Pre-
vious studies in Latin America have reported a prevalence of cognitive
impairment between 1% to 28% in the general population [5,6], whereas
dementia was present in 3.4% to 7.1% [6,7]. The wide range reported for
these estimates depend on the method used, i.e. screening tools or spe-
cialized clinical assessment. Within the arsenal of screening tools,
several tests including the modiﬁed Minimental State Examination
(MMSE), Leganés Cognitive Test (LCT), Montreal Cognitive Assessment
(MoCA), and others have been validated against international guide-
lines or clinical plus an assessment battery for cognitive impairment
diagnosis.
Even when international guidelines [8,9] recommend older adults
(i.e. those aged ≥65 years) should be assessed for cognitive impairment,
yet a deﬁnite diagnosis of cognitive impairment is cumbersome and
must be performed by a neurologist [10,11]. However, other guidelines
and researchers concluded that the evidence is insufﬁcient to assess the
balance of harms and beneﬁts of the screening [12,13]. Therefore, utility
of cognitive screening is still controversial.Moreover, there are reported
different strategies for screening i.e. use of one test, two test in combina-
tion and nowadays there is not agreement in the best method of evalu-
ation [14]. Another issue is that several older adults, especially in low-
and middle-income countries, live in remote rural regions or urban
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areas without access to specialized services that could offer routine
screenings; hence, the need to have simple and rapid screening tools
to assess cognitive impairment.
Most of the epidemiological studies using different tests for cogni-
tive impairment and dementia have been developed and validated in
high-income countries where language, socioeconomic status, educa-
tion level, and access to healthcare are different from Latin America.
The literature on the topic arising from Latin America is scant, coming
mainly from Brazil. For example, there are studies adapting and validat-
ing theMMSE in Brazil, but also studying the effect of age and education
on results, as well as assessed different cut-offs [15–17]. Moreover, a
previous study used theMMSE in a rural populationwith low education
[18]. In addition, MoCA has been also validated in Brazil [19]. In Ecuador
some studies have used LCT and MoCA [20,21]. Despite of this, there is
limited data available evaluating the performance of these screening
tools to diagnose or suggest cognitive impairment in Latin American
and its rural areas [22].
The aim of this study was to determine the bias and agreement be-
tween the MMSE, MoCA and LCT for screening of cognitive impairment
among participants with hypertension in a semi-urban area in Peru, and
to provide evidence about the need to have more appropriate tools
given current changes in the population trends and recent efforts by
the Peruvian government to improve the quality of life among poor
older adults [23].
2. Methods
2.1. Ethics
The Institutional Review Board of the Universidad Peruana Cayetano
Heredia, Lima, Peru, approved this protocol. Oral informed consent was
obtained from all participants due to high rates of illiteracy.
2.2. Study design, setting and participants
This study was performed in the semi-urban area of Tumbes, lo-
cated in the northern coast of Peru, near the border with Ecuador,
where the traditional agricultural landscape has become intermixed
with rapidly growing urban sections. As people with hypertension
are at higher risk of cognitive impairment, participants were a sub-
sample of those originally enrolled in the Tumbes site of the
CRONICAS Cohort Study [24], speciﬁcally those aged ≥65 years and
classiﬁed as having a diagnosis of hypertension at baseline in
2010–2011. Hypertension was deﬁned according to international
guidelines: systolic blood pressure ≥ 140 mm Hg or diastolic blood
pressure ≥ 90 mm Hg using the mean of the last two of three blood
pressure (BP) measures, or self-report of physician diagnosis and
currently receiving antihypertensive medication [25]. All partici-
pants who met the inclusion criteria were re-contacted during Octo-
ber and November of 2014 to be assessed with the screening tools for
cognitive impairment.
2.3. Cognitive evaluation
Three different screening tools were used; each has been previously
translated into Spanish and used in different Spanish-speaking countries.
Our evaluationwas conducted during three consecutive days. Every day,
a trained staff performed one of the tests in the following order: MMSE
was applied on the ﬁrst day, followed by the Leganés on the second
day, and theMoCAon the last day. Thismethodwas used to avoid fatigue
given the similarity of questions across tools as well as to ensure a stan-
dardized procedure for the evaluation of the participants.
ThemodiﬁedMinimental State Examination (MMSE)was validated in
Spanish in Chile, contains six questions with a maximum score of 19
points. A cutoff of 13 points or lower suggests cognitive impairment [26,
27]. Items assessed in the tool are registration, orientation, delayed recall,
attention/concentration, visual-spacial ability and verbal comprehension.
The Montreal Cognitive Assessment (MoCA), validated in Colombia
[28], is a 30-point assessment tool comprising 11 questions. According
to the manual we added one point for an individual who has 12 years
or fewer of formal education. A cutoff ≤25 points indicates cognitive im-
pairment [29]. Items evaluated in this tool are attention and concentra-
tion, executive functions, memory, language, conceptual thinking,
calculation, visuoconstructional skills, and orientation.
The Leganés Cognitive Test (LCT) was validated in Spanish in Spain
[30]. The tool contains 12 questionswith amaximum score of 32 points,
and a cutoff point of 22 is used for determining cognitive impairment
[31]. Items included in this tool are temporal orientation, spatial orien-
tation, personal information, naming test, immediate memory, late
memory and logical memory.
2.4. Other variables
We collected demographic information: age, sex, education level
(none/initial, primary, secondary or higher), marital status (single, with
partner, divorce/widowed), currently working, socioeconomic status
based on possessions weighted asset index, and split in tertiles. With
regards to hypertension status, we collected time of disease in years, anti-
hypertensive treatment, and control of blood pressure deﬁned as systolic
blood pressure b 140 mg/dL and diastolic blood pressure b 90 mm Hg.
Lifestyles variables included smoking status (never, former, current
smoker), hazardous drinking, evaluated using the Alcohol Use Disorder
Identiﬁcation Test [32], physical activity using the leisure time and
transport-related domain of the International Physical Activity Ques-
tionnaire (IPAQ) [33,34], and access to healthcare (yes/no).
Other important clinical variables such as the presence of depressive
symptoms using the Center for Epidemiological Studies Depression
(CES-D) with a cutoff of 16 points; type 2 diabetes mellitus, deﬁned as
fasting glucose ≥126 mg/dL [≥7 mmol/L] or self-report of physician di-
agnosis and currently receiving anti-diabetic medication [35]; current
self-reported history of stroke, body mass index (BMI) categories (nor-
mal if BMI ≥ 18.5 and b25 kg/m2, overweight ≥ 25 and b30 kg/m2, and
obese ≥ 30 kg/m2) [36], were also evaluated.
2.5. Statistical analysis
STATA12 forWindows (Stata Corp, College Station, TX)was used for
analysis. Prevalence of cognitive impairment using MMSE, MoCA and
LCT and their respective 95% conﬁdence intervals (95% CI) were esti-
mated. Mean and standard deviation (SD) or median and interquartile
range (IQR) were utilized to describe the distribution of quantitative
variables. To allow for comparisons between tests, we used non-
standardized (raw scores) and standardized (z-score) values of MMSE,
MoCA and LCT. This standardization technique rescaled raw scores
into a new variablewith amean of 0 and a standard deviation of 1. Pear-
son correlation coefﬁcients (r) were calculated to measure the strength
of the linear relationship between two tests. As previous studies com-
paring two quantitative methods using correlation have been criticized,
Bland-Altman plots, calculated using the difference between the
methods (X − Y) against the average of them (X + Y) / 2 [37], were
used. This simple parametric approach allows us to assess error and
bias, spot outliers and detect trends.
Finally, using each of the score's cutoff values for cognitive impair-
ment, Kappa statistics (κ) were calculated.
3. Results
3.1. Description of participants
From the 1160 participants recruited in the CRONICAS Cohort Study,
a total of 146 had the diagnosis of hypertension andwere aged ≥ 65 years
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old. Of them, 143 were re-contacted, but 4 (2.8%) were excluded due to
their visual impairment (blindness). Detailed information regarding se-
lection of participants is shown in Online E-Fig. 1. Therefore, only 139
were assessed for cognitive impairment, their mean age was 76.5 years
(SD 6.9) and 56.1% were females. A total of 74/139 (53.6%) lived with a
partner, 108/139 (77.7%) had only primary education level, 44/139
(31.7%) still worked. Sociodemographic and lifestyle characteristics are
show in Table 1.
Subjects had a median time of hypertension of 8.3 years (IQR: 5.5–
13.8), 80/139 (58.7%) reported currently receiving antihypertensive
medication, and 55/139 (39.6%) had their blood pressure under control.
Other comorbidities such as depression, type 2 diabetes mellitus, and
history of stroke are show in Table 2.
3.2. Cognitive evaluation
Cognitive impairment was present in 63.3% of individuals (mean
score: 12.4, SD 3.8) when using the MMSE; in 28.1% (mean score:
23.9, SD 3.6) when using the LCT; and in 100% (mean score 14. 8, SD
4.5) when using the MoCA.
The correlation between z-MMSE and z-LCT was 0.597 (p b 0.001),
between z-MMSE and z-MoCA was 0.698 (p b 0.001), and between z-
LCT and z-MoCA was 0.501 (p b 0.001). A scatter plot of standardized
scores correlations is shown in Fig. 1, whereas Online E-Fig. 2 shows
scatter plots using raw scores.
3.3. Bias and agreement between tools
Bland-Altman plots conﬁrmed bias between the tools. The z-MMSE
and z-LCT (Fig. 2a) had a limit of agreement from −1.795 to 1.795.
The z-MMSE and z-MoCA (Fig. 2b) had a limit of agreement from
−1.553 to 1.553. Finally, z-LCT and z-MoCA had a limit of agreement
from−1.999 to−1.999. Online E-Fig. 3 presents Bland-Altman plots
using raw scores.
Agreement, as per κ statistic, between theMMSE and LCTwas 60.4%,
betweenMMSE and MoCAwas 63.3%, and between MoCA and LCT was
28.1%.
4. Discussion
4.1. Main ﬁndings
We used three different well-established screening tools for cogni-
tive impairment in elderly participants with hypertension, low educa-
tional level, and low socioeconomic status from a semi-urban area in
Peru and found large discrepancies in the rates of cognitive impairment:
one third of subjects were classiﬁed as having cognitive impairment
with the LCT, two thirds with the MMSE, and all of them with the
MoCA. Despite of the correlation observed between tools, bias according
to Bland-Altman plots showed that for greater levels of cognitive im-
pairment the spread of points around themean also increased, suggest-
ing that the agreement between tests is lower in persons with greater
scores of cognitive impairment, even whenmost of the points are with-
in one standard deviation. As a result, all the tools evaluated showed di-
verse results and, as such, these observations call for a major need to
initiate work towards ﬁnding an appropriate tool or appropriate cutoff
point for cognitive impairment screening in low-resource settings
where the population has similar characteristics to the onesmentioned:
low level of education and income. Anticipating a rise in the burden re-
lated to cognitive impairment in economies in transition togetherwith a
well-known problem of shortage of specialized human resources, this
study signals towards a major gap and challenge for the years to come.
4.2. Comparison with other studies
The different domains evaluated by each test might explain the dis-
similar results found in our study. For example, whereas the three tests
evaluated orientation,MMSE andMoCA evaluated attention and visual-
spatial ability, MMSE and LCT evaluated registration and delayed recall,
and MoCA and LCT evaluated memory. Prior studies have reported that
MoCA has greater sensitivity and speciﬁcity compared to the MMSE for
Table 1
Characteristics of participants with hypertension.
N = 139
Sociodemographic variables
Age, mean (SD) 76.5 (6.9)
Female, n (%) 78 (56.1)
Marital status, n (%)
Single 8 (5.8)
With partner 74 (53.6)
Divorce/widowed 7 (40.6)
Individual's education level, n (%)
Illiterate 18 (12.9)
Primary 108 (77.7)
Secondary 13 (9.4)
Possessions weighted asset index, n (%)
Lowest tertile 5 (46.8)
Middle 50 (35.9)
Highest tertile 24 (17.3)
Currently working, n (%)
Yes 44 (31.7)
Smoking, n (%)
Never smoke 85 (61.1)
Former smoker 45 (32.4)
Current smoker 9 (6.5)
Hazardous drinking, n (%)
Yes 5 (3.6)
Leisure-time physical activity, n (%)
Low 134 (96.4)
Moderate/high 5 (3.6)
Transport-related physical activity, n (%)
Low 110 (79.1)
Moderate/high 29 (20.9)
Access to healthcare
Yes 109 (80.2)
SD = standard deviation
Table 2
Clinical variables of study population.
N = 139
Depressive symptoms, n (%)
Yes 26 (18.7)
Type 2 diabetes mellitus, n (%)
Yes 22 (15.8)
Stroke, n (%)
Yes 1 (0.7)
Body mass index, n (%)
Normal 43 (30.9)
Overweight 59 (42.5)
Obese 37 (26.6)
Antihypertensive treatment, n (%)
Yes 80 (57.6)
Control blood pressure, n (%)
Yes 55 (39.6)
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screening of cognitive impairment [38]. On the other hand, however,
the LCT is a tool easy to administer, and, as theMoCA, is less susceptible
to educational level, perhaps because the MMSE includes calculation
and drawing. Another important point is that we applied the abbreviat-
ed version of the MMSE, even when the original instrument had been
developed for low-educated population, the validation is from Chile,
who has a population with higher levels of education than Peru [27].
There is scarce information regarding the comparison of the perfor-
mance of different cognitive impairment tools, especially in low- and
middle-income countries or rural settings. For example, a study from
Brazil enrolling low-educated elderly individuals found that 11.8% had
cognitive impairment using LCT and 37.2% using MMSE, and a poor
agreement using Kappa was reported between tests [39]. Similarly, an-
other study in United States used Bland-Altman plots to assess the
agreement between Alzheimer's Disease Assessment Scale – Cognitive
(ADAS-Cog), Clinical Dementia Rating (CDR), and the MMSE and
found that poor agreement between tests was a function of increasing
cognitive impairment [40] as our results also suggest.
4.3. Public health relevance
As the world population ages, including large populations in low-
and middle-income countries, the probability of having cognitive im-
pairment also increases. Cognitive impairment translates into individ-
uals who require special care both at home and by state services.
Evenwhen in last years the screening of cognitive impairment, espe-
cially in elderly, is controversial [12], screening is still apply and current-
ly, most health systems face major shortages of human resources, and
more specialists in the ﬁelds of neurology are needed [41]. Although
our study has not been performed to support conclusions about the per-
formance of any screening tool or to identify which one was better, our
ﬁndings suggest the potential misclassiﬁcation of individuals with a
condition of cognitive impairment with further impact in clinical prac-
tice, disease burden, and policy implications, at least in people with hy-
pertension. Apparently, for a low-income scenario as in the case of this
study, the LCT is less susceptible to education level in comparison to
MMSE, as suggested by literature [30]. In the case of MMSE, previous
studies have found that age and education could explain 12% of the var-
iability in results [42].
Tests for cognitive impairment should have the following features:
easily administered, promptness of results, and be performed by any
health professional or even community health workers. However,
once a case is detected using any of the screening tools, a battery of
other evaluations, laboratory, and imaging tests are needed to conﬁrm
the diagnosis of cognitive impairment. For this reason, a testwith higher
speciﬁcity than sensitivity would be favored as there is no effective
treatment for cognitive impairment, but some preventive measures
can be taken to delay progress. As a result, false-positive cases would
be reduced, together with lesser burden and costs for the patient and
its family.
4.4. Strengths and limitations
This study assessed three cognitive impairment tools in a resource-
constrained setting in Peru. As these tools have been generated and val-
idated for individuals in high-income settings, studies from other set-
tings, including Latin America, are needed to account for appropriate
cultural and income validation. This is one of the few studies applied
in Spanish speakers from a semi-urban population in Latin America.
Nonetheless, this study has some limitations. First, the ﬁndings of
this report cannot be generalized to other settings, as the particular
characteristics of the study population — presence of hypertension,
low educational level, and low socioeconomic status —might partially
explain differences. Our sample included only participants with hyper-
tension reducing the external validity of the ﬁndings and limited the ap-
proach of providing evidence about the need of more adequate
instruments. Yet, our results can well serve as a unique opportunity to
explore the functioning of such tools in difﬁcult ﬁeldwork circum-
stances. Second, we did not assess the performance of these screening
tools by comparing them with a gold standard test, and therefore we
could not estimate sensitivity and speciﬁcity estimates neither choose
the better tool to study cognitive impairment in future studies. Third,
we used cut-off points validated to other populations with different
characteristics to our sample. Even when this partially explains the
low rate of agreement, these cut-off points are used in clinical practice
Fig. 1. Scatter plots of cognitive impairment tools. ▲ z-modiﬁed Minimental State Examination (axial x) and z-Leganés Cognitive Test (axial y). ○ z-modiﬁed Minimental State
Examination (axial x) and z-Montreal Cognitive Assessment (axial y). ♦ z-Leganés Cognitive Test (axial x) and z-Montreal Cognitive Assessment (axial y).
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in most countries of Spanish language [43]. Therefore, physicians could
classify a patient as cognitive impaired depending upon the tool utilized.
Fourth, we did not use the original MMSE test but the abbreviated ver-
sion of the MMSE validated in Chile [27,44]. As this short version does
not include abstract thinking, it is appealing for low educated popula-
tion, although comparisons need to be done with caution. Finally, the
tests were applied to participants in the same order instead of random
order with the purpose of standardizing the assessment of the
participants.
5. Conclusions
This study shows that three of the most common tools available to
assess cognitive impairment in the elderly population have poor agree-
ment in resource-constrained settings in a Latin America country. This
calls for attention in two different ways, ﬁrst, our results support the
controversy of screening cognitive impairment and, second, the need
of ﬁnding themore appropriate screening tool for cognitive impairment
in low-resource settings.
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